Ionis Pharmaceuticals, Inc.
IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipā¦ read more
Healthcare
Biotechnology
34 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$82.70
Price+2.19%
$1.77
1Y
Price
Market Cap
$13.142b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-60.2%
EBITDA Margin-82.1%
Net Profit Margin-86.0%
Free Cash Flow MarginRevenue
$966.956m
+37.1%
1y CAGR+20.3%
3y CAGR+8.3%
5y CAGREarnings
-$256.342m
+43.5%
1y CAGR-5.4%
3y CAGR-214.8%
5y CAGREPS
-$1.71
+43.8%
1y CAGR-3.2%
3y CAGR-214.9%
5y CAGRBook Value
$617.967m
$3.033b
Assets$2.415b
Liabilities$1.489b
DebtDebt to Assets
49.1%
-10.3x
Debt to EBITDAFree Cash Flow
-$302.662m
+44.6%
1y CAGR-10.7%
3y CAGR-603.8%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company